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Abstract. A quantitative, competitive RT-PCR-RFLP assay 
was developed to detect and discriminate the expression of 
mutant versus wild-type alleles of the Ki-ras oncogene. The 
aim was to establish whether these alleles are differentially 
expressed in human malignant neoplasma, since experiments 
in vitro have shown stoichiometric representation and 
expression of ras genes does not necessarily engender a 
cancer phenotype. Sixteen primary colorectal carcinomas and 
two colorectal carcinoma xenografts, passed in immune-
suppressed mice, were studied. Previous sequence analysis 
had established that 9 of the primary tumours and both 
xenografts had codon 12 Ki-ras mutations, 4 tumours had 
codon 13 mutations and 3 were wild-type controls. Wild-type 
and mutant Ki-ras were co-expressed in all the primary 
tumours, but the assay showed that stoichiometrically 
equivalent amounts of the two mRNA species were present in 
only one-third: in the others, mutant Ki-ras was 
overexpressed by around 30-60% relative to wild-type. The 
xenografts showed a similar range of values, despite their 
near-total lack of stroma. Ki-ras activation by point mutation 
is known to be involved in the early, adenoma phase of 
evolution of colorectal tumorigenesis, but these results show 
that differential expression of the mutant allele is common in 
carcinomas and may be associated with persisting growth 
advantage. 
Introduction 
Genetic alterations are known to be responsible for cancer. 
The initiation, progression and promotion of tumours has 
been associated with a sequence of such genetic aberrations 
involving oncogenes and oncosuppressor genes (1,2). In 
human colorectal cancer several of these critically altered 
genes are known, including APC, MCC, Ki-ras, DCC and 
p53 (3,4). The alterations in the function of these genes may 
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be responsible for specific stages of tumorigenesis and 
cancer progression (3). Activation of Ki-ras by point 
mutations at codons 12, 13 and 61 appears in the 
premalignant phase of colorectal tumorigenesis, being 
observed in the larger (and more dysplastic) adenomas. 
Carcinomas show the same spectrum of mutations, at 
approximately the same incidence, around 40-50%. 
In a variety of experimental systems, expression of 
activated ras genes is associated with early stages of 
carcinogenesis, being apparently responsible for both 
initiation and progression (1,2,5-8). Recent work, however, 
has emphasised the importance of gene dosage in the 
phenotype of cells bearing ras oncogenes (9-11). Whilst the 
presence of mutated and wild-type ras genes in 
stoichiometrically equivalent amounts may have little effect 
on phenotype (12), chemically-induced carcinomas and 
papillomas of skin frequently differ in that carcinomas tend 
to have more gene copies of mutated than wild-type ras 
(6,9,10). 
In this study we sought to characterize more fully the role 
of Ki-ras in human colorectal cancer. In view of reports that 
ras p21 is less abundant in advanced than in early tumours 
(22), we asked whether expression of the abnormal Ki-ras 
oncogene makes a continuing contribution to the 
development of malignant tumours. We also asked whether 
wild-type and mutated genes are equally expressed. To do 
this we developed a competitive RT-PCR-RFLP assay 
(13,14) using an exon connection strategy in which an 
antisense primer within exon 3 was coupled with the sense 
primer in exon 1 already described (15). The exon 3 primer 
also bore a nucleotide mismatch that created a BstNI site at 
the 3' end of the PCR product. This controlled for digestion 
efficiency at a second BstNI site at the 5' end of the product, 
which was destroyed by mutation in codon 12 (Fig. 1). 
Using this technique we examined the ratio of expression 
of wild-type and mutant Ki-ras genes in primary colorectal 
cancers in man. The results show that mutant Ki-ras, when 
present, is always expressed, and its expression often exceeds 
that of wild-type allele. 
Materials and methods 
Tumour material. Tumour fragments from colorectal 
carcinomas were snap frozen in liquid nitrogen after surgery 
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and stored at -70°C. All tissues were carefully trimmed to 
remove as much non-neoplastic tissue as possible. A total of 
16 colorectal carcinomas were examined, 9 with known 
codon 12 Ki-ras mutations, 4 with codon 13 mutations and 3 
without mutation. To control for the effect of non-neoplastic 
stromal cells on the analysis, two further carcinomas were 
studied following multiple passage as xenografts in immune-
suppressed mice. Although such xenografts faithfully 
reproduce the histology and genetic defects of the primary 
tumours (16), they possess little non-neoplastic stroma, 
which in any case is of murine origin and so affords an 
inefficient template for the human-specific PCR primers. 
Cell lines. Two human colon carcinoma cell lines Colo 320 
and SW 480 were employed for quantitative determination of 
the ratio between normal versus mutant Ki-rai transcripts: 
Colo 320 cells express only wild-type Ki-ras, whilst SW 480 
express only Ki-ras with a codon 12 mutation. 
RNA extraction. RNA was extracted by the RNazol Β kit 
(BioGenesis) which is a modified version of the guanidinium 
isothiocyanate method. In brief, approximately 10 mg of 
frozen tissue were homogenized in 800 μΐ RNazol B. After 
addition of 100 μΐ chloroform the mixture was shaken 
vigorously and centrifuged for 20 mins at 12000g at 4°C. The 
supernatant was collected and the RNA precipitated with an 
equal volume of isopropanol. The RNA pellet was washed 
sequentially with 4M LiCl and 75% ethanol. 
The quality and quantity of RNA was assessed by 
formaldehyde denaturing agarose gel electrophoresis and 
spectrophotometry at 260 nm and 280 nm. 
cDNA synthesis. 1 μg of total RNA was primed with 0.5 μg 
oligo-dT and the reaction was performed in a final volume of 
20 μΐ with 200 U MMLV reverse transcriptase (BRL) 
following the supplier's protocol. After 1 hour at 37°C the 
enzyme was heat inactivated (5 min, 98°C). A negative 
control without RNA was also included. 
PCR amplification. The cDNA was amplified in a 100 μΐ 
reaction (10 mM Tris-HCl pH 8.3, 50 mM KCl, 1.5 mM 
MgCl2, 0.01% Triton, 200 μΜ dNTPs) with 200 ng of each 
primer and 2.5 U Taq polymerase (NBL). The amplimer 
sequences were 
5'-ACTGAATATAAACTTGTGGTAGTTGGACCT-3' and 
5'-CAAATCACATTTATTTCCTAC£AGGACCAT-3'. 
After an extended initial denaturation step (94°C for 4 min) 
the PCR program consisted of 1 min at 94°C, 1.30 min at 
62°C and 1.30 min at 72°C for a total of 25 cycles. 
To exclude false positive results due to K'i-rasl 
pseudogene in DNA still present in the RNA preparations, 
control RNA was subjected to PCR amplification without 
prior incubation with reverse transcriptase. 
PCR amplification for detection of LOH at genomic DNA 
level was performed as described (17,18). 
RFLP analysis. For codon 12 mutations 20 μΐ of the PCR 
reaction were subjected to BstNI (NEB) digestion (20 U) at a 
final volume of 30 μΐ at 60°C for 3 h. For codon 13 mutations 
the same procedure was employed as for codon 12 except 
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Figure 1. (A) Application of competitive RT-PCR-RFLP on Colo 320 RNA 
reveals only normal Ki-rai signal being expressed while in SW 480 only 
codon 12 mutant Ki-ras signal is present. Lane 1: Colo 320, lane 2: 
undigested PCR product, lane 3: SW 480, lane 4: marker. (B) Nucleotide 
substitution in the primers facilitate the creation of two BstNI sites. The 3' 
end site is permanently functional and serves as a control for the efficiency 
of digestion, discriminating RFLP products from undigested PCR products. 
The 5' end site is functional depending upon the presence of codon 12 
mutations. 
HphI (NEB) was used at 37°C. The products were 
electrophoresed through a 3% agarose gel (3 parts Nusieve/1 
part Seakem). Gels were stained with ethidium bromide and 
photographed on an ultraviolet light transilluminator. 
RFLP analysis for detection of LOH was performed as 
described (17,18). 
Ratio quantitation. Total RNA from Colo 320 and SW 480 
cell lines was mixed in the following mass ratios to create 5 
batches of mixtures: 1/1, 0.5/1, 0.25/1, 0.125/1, 0.0625/1 
(Colo 320/SW 480). 3 μg of each mixture was used for the 
RT-PCR-RFLP assay. 
The RFLP products were loaded on 6% mini 
Polyacrylamide gels containing 1% glycerol. Gels were run 
in TBE buffer at 100V for 1 h. After electrophoresis, gels 
were stained in ethidium bromide and photographed on a UV 
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Figure 2. Regression analysis between total RNA ratios of normal versus mutant Ki-ras resulted in a linear relationship described by the equation Y=1.02X-
0.03 with a coefficient of correlation R=0.99. 
transilluminator. The photographs were scanned on a flatbed 
scanner (Microteck) and computer image analysis was 
performed on a Macintosh computer. The densitometric 
values from computer image analysis were statistically 
analysed with the aid of Statworks (1.2) on the same 
computer. 
The RFLP products from tumour samples were analysed 
in the same way. Densitometric values for each tumour taken 
from two independent experiments, and the average values 
were used to compute the ratio between the mutant and wild-
type Ki-ras transcripts, using the cell line data as a 
calibration curve. 
Results 
Ratio quantitation. To obtain reliable measurements for the 
ratio of the level of expression between the trasncripts of the 
Ki-ras locus, we assessed the accuracy of the competitive 
RT-PCR-RFLP assay, using RNA extracted from the two 
human colon carcinoma cell lines Colo 320 (wild-type only) 
and SW 480 (codon 12 mutant only) (Fig. 1). Total RNA 
from these cell lines was mixed in various ratios, as 
described in the Methods and competitive RT-PCR-RFLP 
was performed with various PCR cycles. The ratios of Ki-ras 
obtained after the RFLP analysis was plotted against the 
ratios of the initial total RNA from the two cell lines, giving 
a standard curve (Fig. 2). Under optimum conditions (25 
cycles) the data points closely fit a linear equation (R=0.99). 
The equation describing this standard curve is Y=1.02X-
0.03, indicating a direct linear proportionality between the 
input RNAs and the cDNAs amplified from the transcripts. 
Higher cycle numbers were avoided, however, as this linear 
relationship was lost, presumably because of the 
accumulation of heteroduplex products (13). 
Codon 12 mutation analysis. All 9 carcinomas with codon 12 
mutation expressed both mutated and wild-type Ki-ras 
transcripts (Fig. 3A). Densitometric analysis of the samples 
showed that the ratio of mutated and wild-type transcripts 
was close to unity (0.8-1.0) in only 3 (Table I). In all others, 
mutant Ki-ras was overexpressed relative to wild-type by 30-
60%. All these ratios of wild-type to mutant Ki-ras cDNA 
observed in the carcinomas fall within the range shown to be 
linearly related to transcript in Fig. 2. 
Codon 13 mutation analysis. All 4 cases with codon 13 
mutation had the same Asp 13 mutation in the genomic 
DNA. This mutation creates a recognition site for the HphI 
restriction enzyme which is unique in the amplified cDNA 
fragment. Hence, cDNA mutant from transcripts is digested 
with this enzyme while wild-type cDNA is not affected. 
Analysis of the 4 carcinomas with Aspl3 mutation 
revealed that both mutant and wild-type transcripts were 
expressed in all (Fig. 3C). Because of the lack of a second 
restriction site in the PCR product, the efficiency of digestion 
with the HphI cannot be controlled. For this reason we did 
not attempt to quantify the ratio between the Ki-ras 
transcripts, but qualitatively it was clear that, as with codon 
12 mutations, both mutant and wild-type genes were 
expressed. 
Control tumour tissues. Analysis of the expression of codon 
12 mutant Ki-ras in 2 xenografts showed values that covered 
the same range as the primary tumours: both mutant and 
wild-type alleles were expressed in both xenografts, one in 
near stoichiometric equivalence, the other with the mutant in 
excess by around 70% (Fig. 3B and Table I). As expected, 
the three carcinomas without Ki-ras mutation showed only 
wild-type cDNA (Fig. 3A tracks 2,3,7). 
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Figure 3. Results from the RFLP analysis. (A) codon 12 mutation analysis, 
lanel: undigested product, lanes 2, 3, 7: products from colon carcinomas 
with no codon 12 mutation after RFLP analysis, lanes 4, 5. 6: heterozygous 
products after RFLP analysis, (B) codon 12 xenograft analysis, lane 1: 
undigested product, lanes 2, 3: heterozygous mRNA Ki-ras products from 
xenografts after RFLP analysis, (C) codon 13 mutation detection in four 
heterozygous tumours. 
Table I. Ki-ras codon 12 mutations detected by competitive 
RT-PCR-RFLP analysis in colon tumours and RFLP data 
from polymorphic sites close to or within Ki-ras locus. 
Samples3 Mutationb RNA ratio Rsal 
(wt/mut) 
StuI BstXI 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Xeni 
Xen2 
aXen=Xeno 
Al=allele 1; 
ASP12 
SERI 2 
ASPI 2 
ASP12 
ALA 12 
VAL12 
VAL 12 
ASP 12 
ASP12 
VAL12 
VAL12 
graft tumours; 
A2=allele 2. 
0.66 
0.95 
0.61 
0.77 
0.86 
0.88 
0.68 
0.57 
0.61 
0.98 
0.59 
b
codon 12 
Al 
Al 
Al 
Al 
amino 
A2 
A2 
A1A2 
Al 
A1A2 
Al 
A2 
A1A2 
A1A2 
Al 
A1A2 
A2 
acid substitutions: 
RFLP analysis for loss of heterozygosity at the Ki-ras locus. 
Five of the 9 patients with carcinomas bearing codon 12 
mutations were informative at polymorphic sites close to or 
within Ki-ras2 (Table I). In every case, including 3 
carcinomas in which the ratio of wild-type to mutant 
transcript was less than 0.67, both alleles were clearly present 
within the tumour, apparently in approximately equal 
amounts. Thus there was no evidence for loss of 
heterozygosity at the Ki-ras locus to account for the 
differences in expression between the Ki-ras alleles 
described above. 
We have described a quantitative RT-PCR method capable of 
discriminating mutant from wild-type Ki-ras transcripts in 
human tumour tissues. In this method, the ratio of the two 
species of transcript is a direct linear function of the ratio of 
their amplified, reverse-transcribed cDNAs. We attribute the 
simplicity of this relationship to the fact that no correction is 
required to match the efficiencies of synthesis of the mutant 
and wild-type products: during both reverse transcription and 
the polymerase chain reaction, synthesis of both proceeds 
within the same reaction vessel from the same primers, and 
PCR products are of identical length. Initially we were 
concerned that the relationship between RNA transcript and 
amplified cDNA might be significantly distorted by the 
extent of heteroduplex formation, since this could influence 
the kinetics of denaturation and reannealing. This may have 
been minimised by the relatively low number of cycles used. 
The results show that mutant Ki-ras, if present in 
colorectal carcinoma DNA, is invariably expressed. 
Expression of wild-type Ki-ras never significantly exceeded 
that of the mutant, but often was substantially less. Loss of 
heterozygosity at the Ki-ras locus is unlikely to be the 
explanation for this preferential expression of the mutated 
Ki-ras allele, since a wild-type Ki-ras allele was present 
together with the mutant allele, in every case where this 
could be ascertained. Moreover, LOH involving chromosome 
12p is one of the rarest defects documented in allelotypes of 
large series of human colorectal carcinomas (19), although 
selective loss of wild-type Ki-ras has been documented in a 
small number of cases (20). The data from the cases 
presented here therefore point to the conclusion that mutated 
Ki-ras genes, when present in colorectal carcinoma cells, 
tend to be expressed more than the wild-type genes by virtue 
of a transcriptional or post-transcriptional mechanism. 
Quantitative analysis of data gathered from authentic 
tumour tissue, as here, is often uncertain because of the 
unknown extent to which intra-tumoral stroma contributes 
wild-type products to the tumour extracts. Excess stromal 
RNA would have increased towards unity the ratio of wild-
type transcript to' mutant, however, whereas the majority of 
the tumours studied here showed ratios substantially less than 
unity. Further, the ratio of wild-type to mutant transcripts in 
the xenografted tumours, in which the stromal component is 
negligible, covered the same range of values as in authentic 
primary tumours. 
Many previous studies on a variety of animal and human 
tissues have indicated that mutational activation of ras genes 
is frequently an early event in the evolution of tumours (1,5-
7,21). There is evidence that ras mutations may be influential 
at later stages of tumour progression also (22,23). In 
experiments in which mutant ras genes are selectively 
inactivated by specific recombination events, the pre-existing 
tumour phenotype reverts to a more normal form (23), 
indicating that mutated ras genes are necessary, in these cells 
at any rate, for the maintence of malignant behaviour. On the 
other hand, the mere possession of a mutated ras gene is not 
sufficient for malignant transformation of some cell types 
(5,6,12,25). Factors limiting its transforming potency appear 
to include its level of expression and that of any wild-type 
ras gene in the same cell. We interpret the data presented 
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here to imply that expression of the Ki-ras oncogene may 
confer some survivorship or growth advantage upon tumour 
cel ls even in wel l-es tab l i shed t u m o u r s . In c o n t r a s t , 
expression of the wild-type transcript may be diminished, 
because it is unnecessary for, or limiting to growth. It will be 
of interest to determine whether these early results are 
repeated in larger series of cases, and in particular whether 
the ratio of wild-type to mutant transcript differs between 
carcinomas and adenomas. 
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